The findings revealed a robust interaction between UBE2C+ tumour cells and PARs, the regulatory receptors governing the activity of the cell cycle regulatory kinase ERK1/2,34, 35 thus providing further substantiation for our observations. The gene discussed is MAPK3; the disease is neoplasm.